Epizyme Inc (NASDAQ:EPZM) has received a consensus rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $18.60.
A number of brokerages have issued reports on EPZM. Wedbush reiterated an “outperform” rating and set a $24.00 price target on shares of Epizyme in a research report on Thursday, December 19th. Cowen reiterated a “buy” rating and set a $18.00 price target on shares of Epizyme in a research report on Thursday, October 31st. ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research report on Tuesday, December 31st. Finally, Morgan Stanley upgraded Epizyme from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $12.00 to $22.00 in a research report on Thursday, December 5th.
A number of hedge funds have recently modified their holdings of EPZM. Metropolitan Life Insurance Co NY lifted its position in shares of Epizyme by 18.3% in the first quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 3,029 shares in the last quarter. FMR LLC increased its holdings in shares of Epizyme by 0.3% in the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after purchasing an additional 11,759 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Epizyme in the second quarter valued at approximately $1,032,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Epizyme by 20.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 459,308 shares of the biopharmaceutical company’s stock valued at $5,765,000 after purchasing an additional 77,012 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Epizyme by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 316,862 shares of the biopharmaceutical company’s stock valued at $3,976,000 after purchasing an additional 45,110 shares during the last quarter. Institutional investors own 86.95% of the company’s stock.
Shares of EPZM opened at $26.72 on Wednesday. Epizyme has a 52 week low of $8.80 and a 52 week high of $27.05. The company has a quick ratio of 10.90, a current ratio of 10.90 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -16.60 and a beta of 2.68. The stock’s 50-day moving average price is $21.02 and its 200-day moving average price is $14.73.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. The firm had revenue of $5.72 million for the quarter, compared to the consensus estimate of $5.50 million. As a group, equities analysts anticipate that Epizyme will post -1.88 EPS for the current fiscal year.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Article: Inverted Yield Curve
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.